A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

NCT02381886 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

166

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies That Harbor IDHR132 Mutations

Interventions

DRUG: IDH305

Sponsor

Novartis Pharmaceuticals